

Elekta leaders present retrospective and future developments to investor community

STOCKHOLM – Elekta (EKTA-B.ST) will host its Investor Update at the company's global headquarters in Stockholm, where key members of the management team – including President and CEO Jonas Bolander and CFO Tobias Hägglov – will present Elekta's innovative portfolio, market development, and future growth prospects.

The event will highlight current market dynamics, the strong fundamentals of the radiation therapy industry, and Elekta's roadmap to achieving its mid-term financial targets: restoring gross margin to pre-pandemic levels and reaching an EBIT margin of at least 14%.

As part of its commitment to operational excellence, Elekta will also share the results of a proactive order review aimed to improve the quality of the backlog resulting in improved profitability and predictability. This review resulted in a cancellation valued at SEK 4.9 billion, including orders to be cancelled after year-end FY24/25. As a result, also including the positive net effects of sales and new orders of SEK 1.7 billion and a negative impact of SEK 4.3 billion in foreign exchange, the revised figure for the backlog stands at SEK 36.9 billion.

Habib Nehme, Chief Commercial Officer and Ardie Ermers, Executive Vice President, Region Americas will provide a commercial update. They will discuss the strong market reception of Elekta's latest linear accelerator, Evo, in Europe and the Asia-Pacific region, as well as the company's competitive positioning in North America.

Christopher Busch, President of Linac and Software Solutions, will present the latest technological advancements and opportunities within Elekta's linac portfolio, including Elekta Unity MR-Linac and Elekta Evo integrated with Elekta ONE Planning software. His presentation will emphasize the growing importance of adaptive radiation therapy in improving clinical outcomes and operational efficiency.

John Lapré, President Brachy and Neuro Solutions, will discuss the positive technical and commercial momentum in these business lines and their strategic contribution to Elekta's overall performance.

To attend – either online or in person – and for more information, please register at: <https://events.elekta.com/Investor-Update>. A recording of the Investor Update will be available on Elekta's website following the event.

#

For further information, please contact:

Mattias Thorsson, Vice President, Head of Corporate Communications

Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com

Time zone: CET: Central European Time

Peter Nyquist, Vice President, Head of Investor Relations

Tel: +46 70 575 2906, e-mail: peter.nyquist@elekta.com



Time zone: CET: Central European Time

About Elekta

As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,500 employees combine passion, science, and imagination to profoundly change cancer care. We don't just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit [elekta.com](https://www.elekta.com).